Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era

Clinical Infectious Diseases

Volumn 53, Issue 1, 2011, Pages 84-91

  Bedimo, Roger J ^a   Westfall, Andrew O ^b   Drechsler, Henning ^a   Vidiella, Gabriela ^d   Tebas, Pablo ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Centro de Estudios Infectologicos   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; TENOFOVIR;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PHOSPHONIC ACIDS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STROKE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 79958833758     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir269     Document Type: Article

References (51)

1. Klein D, Hurley L, Quesenberry C, Silverberg M, Horberg M, Sidney S. Hospitalizations for CHD and MI among Northern California HIV1 and HIV- men: changes in practice and Framingham risk scores. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, 2006.
2. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-7.
3. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29-35.
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12. (Pubitemid 47037350)
5. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-31. (Pubitemid 46871511)
6. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-30. (Pubitemid 40347381)
7. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-8.
8. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
9. Smith C, Group DADS. Association between modifiable and nonmodifiable risk factors and specific causes of death in the HAART Era: the data collection on adverse events of anti-HIV drugs study [abstract 145]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
10. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007; 23:567-83, vii. (Pubitemid 47042341)
11. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7:404-10. (Pubitemid 44123252)
12. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35. (Pubitemid 46658704)
13. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
14. Strategies for Management of Anti-Retroviral Therapy/INSIGHT and the D:A:D study groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-24.
15. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26.
16. Hurley LB, LeydenW, Xu L, et al. Updated Surveillance of Cardiovascular Event Rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008 [abstract 710]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada. 2009.
17. Palella FJ Jr, Baker RK, Moorman AC, et al.Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
18. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr 2003; 33:506-12. (Pubitemid 36886080)
19. Lee MH, Yang HI, Wang CH, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41:2894-900.
20. Butt A, Xiaoqiang W, Budoff M. Hepatitis C virus infection and the risk of coronary disease [abstract V-4219]. In: Program and abstracts of the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008). Washington, DC: American Society for Microbiology and the Infectious Diseases Society of America, 2008.
21. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11:462-8.
22. Freiberg MS, ChengDM, Kraemer KL, Saitz R, Kuller LH, Samet JH. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007; 21:193-7. (Pubitemid 46036927)
23. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351:1344-6. (Pubitemid 39258430)
24. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 2007; 4:e270.
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-305.
26. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1- infected patients. AIDS; 2010; 24:387-94.
27. Backus L, Mole L, Chang S, Deyton L. The Immunology Case Registry. J Clin Epidemiol 2001; 54(Suppl 1):S12-15. (Pubitemid 34013686)
28. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10. (Pubitemid 36237039)
29. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121: 651-8.
30. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care 2006; 44:S25-30. (Pubitemid 44284254)
31. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-54. (Pubitemid 39532246)
32. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study. J Infect Dis 2010; 201:318-30.
33. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11:130-6.
34. Post FA, Campbell LJ. Abacavir and increased risk of myocardial infarction. Lancet 2008; 372:803; author reply 804-805.
35. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-87. (Pubitemid 351535369)
36. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24:1781-4.
37. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
38. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-8.
39. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
40. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
41. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-9.
42. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-27.
43. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008; 49:499-506.
44. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003; 110:93-8. (Pubitemid 37329447)
45. de Larranaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCVcoinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006; 25:98-103. (Pubitemid 43333670)
46. Martin A, Amin J, Cooper DA, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657-63.
47. McComsey GA, Smith KY, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/ lamivudine or tenofovir/emtricitabine: the HEAT Study [abstract 732]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
48. Palella F, Grange S, Elion R, et al. Inflammatory markers among abacavir and non-abacavir recipients in the Womens' Interagency HIV Study and the Multicenter AIDS Cohort Study [abstract 150B]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
49. Martinez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-9.
50. Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW. Markers of inflammation and coagulation indicate a prothrombotic state in HIVinfected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther 2010; 7:9.
51. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-7.